Testosterone Cypionate Monitoring Schedule: Labs & Exams Your Clinician Should Order

How Testosterone Cypionate Works: Mechanism and Pharmacokinetics

Testosterone cypionate is an esterified form of endogenous testosterone. After intramuscular or subcutaneous injection, esterases in the tissue cleave the cypionate ester, releasing free testosterone into circulation over 7 to 14 days. This depot effect is what separates it from unesterified testosterone and allows once-weekly or twice-weekly dosing.

Androgen Receptor Binding

Free testosterone binds androgen receptors (AR) in muscle, bone, brain, prostate, and hematopoietic tissue. The AR-ligand complex translocates to the nucleus and modulates gene transcription, producing the downstream effects clinicians monitor: erythropoiesis, bone mineral density (BMD) changes, libido, and lean mass accrual. Testosterone's genomic actions are reviewed in detail at the NIH endocrine resource.

Aromatization and DHT Conversion

Roughly 0.3% of circulating testosterone is aromatized to estradiol (E2) by the CYP19A1 enzyme in adipose, liver, and brain tissue. A separate pathway via 5-alpha-reductase converts testosterone to dihydrotestosterone (DHT), the primary androgen in prostate and skin. Both metabolites require monitoring. Elevated E2 can cause gynecomastia and fluid retention; elevated DHT drives prostate growth. The FDA label for testosterone cypionate injection summarizes both pathways.

Half-Life and Trough Timing

The elimination half-life of testosterone cypionate is approximately 8 days. Serum levels peak 24 to 72 hours post-injection and trough just before the next dose. Clinicians draw trough levels (just before the next scheduled injection) to standardize comparisons across visits and avoid measuring a supraphysiologic peak. PubMed pharmacokinetic data on testosterone esters supports this trough-draw convention.

Why a Formal Monitoring Schedule Matters

Testosterone cypionate is not a set-and-forget medication. The T-Trials (N=790 men aged 65 or older with confirmed hypogonadism) demonstrated improvements in sexual function, mood, and walking distance with testosterone therapy, but the authors also documented a statistically significant increase in coronary artery non-calcified plaque volume in the testosterone arm compared to placebo (P<0.001 for plaque volume change in the cardiovascular sub-trial). T-Trials primary report, NEJM 2016.

That single finding illustrates why monitoring is not optional. Clinicians need serial data to detect hematologic, cardiovascular, and prostate signals early enough to intervene.

Baseline Labs: The Pre-Treatment Panel

Every patient starting testosterone cypionate should complete a baseline panel before the first injection. This panel establishes the patient's individual reference point and screens for contraindications.

Core Baseline Tests

• Serum total testosterone (morning draw, 8 to 10 a.m., two separate occasions per Endocrine Society guideline) Endocrine Society Clinical Practice Guideline on Male Hypogonadism, 2018.
• LH and FSH to confirm primary vs. Secondary hypogonadism
• Sex hormone-binding globulin (SHBG) to calculate free testosterone when SHBG is abnormal
• Complete blood count (CBC) with hematocrit and hemoglobin
• Comprehensive metabolic panel (CMP)
• Lipid panel (fasting preferred)
• PSA (in men 40 years or older, or any man with a family history of prostate cancer)
• Estradiol (sensitive assay, LC-MS/MS method preferred)
• Prolactin (to exclude prolactinoma as a cause of secondary hypogonadism)
• Bone mineral density (DXA scan) if the patient has osteoporosis risk factors or a history of fragility fracture

Why Two Morning Draws for Testosterone?

Serum testosterone varies by 10 to 20% within a single individual across the same morning, and exhibits a circadian peak between 6 and 10 a.m. The Endocrine Society 2018 guideline requires two separate low morning readings to confirm hypogonadism before initiating therapy. Bhasin S et al., J Clin Endocrinol Metab, 2018. Skipping this step risks treating men who are not truly hypogonadal.

The 6 to 8 Week Check: First On-Therapy Draw

Six to eight weeks after starting testosterone cypionate (or after any dose change), a trough draw should be taken immediately before the next injection.

What to Measure at 6 to 8 Weeks

• Serum total testosterone (trough), target 400 to 700 ng/dL for most men on standard replacement doses
• Hematocrit, the earliest hematologic signal usually appears by week 6 to 8
• Estradiol (sensitive assay), guides aromatase inhibitor decisions if gynecomastia or fluid retention is present
• Symptom reassessment, use a validated instrument such as the ADAM questionnaire or the Aging Males' Symptoms (AMS) scale

If the trough testosterone is below 400 ng/dL, a dose increase or injection frequency adjustment is appropriate. If the trough exceeds 700 ng/dL, a dose reduction prevents supraphysiologic exposure. FDA prescribing information for testosterone cypionate injection.

Hematocrit at the 6 to 8 Week Mark

Testosterone stimulates erythropoietin (EPO) secretion and expands red cell mass. In the T-Trials, hematocrit exceeded 54% in a greater proportion of testosterone-treated men than placebo-treated men. The Endocrine Society guideline sets 54% as the threshold above which testosterone should be withheld or the dose reduced, because hematocrit above that level raises blood viscosity and thrombotic risk. Endocrine Society guideline, 2018.

The 3-Month Visit: Comprehensive Safety Check

The 3-month visit is the first full safety review. By this point, the patient has had enough cycles to establish steady-state pharmacokinetics, and PSA changes attributable to testosterone (rather than pre-existing prostate disease) begin to emerge.

Labs at 3 Months

• Serum total testosterone (trough)
• CBC with hematocrit
• PSA (if baseline PSA was drawn)
• Estradiol (sensitive assay, if symptomatic)
• LFTs if the patient is on any hepatotoxic agents

PSA Interpretation at 3 Months

A PSA rise of more than 1.4 ng/mL above baseline within the first 3 to 6 months of testosterone therapy should prompt urologic referral, according to the Endocrine Society. Bhasin S et al., 2018. A one-time absolute PSA above 4.0 ng/mL (or above 3.0 ng/mL in high-risk men) also warrants urology evaluation. The concern is not that testosterone causes de novo prostate cancer. The concern is that testosterone may accelerate growth of occult, pre-existing prostate cancer that was below the PSA detection threshold at baseline.

The HealthRX 3-Month Decision Framework

| Finding | Action | |---|---| | Trough T <400 ng/dL | Increase dose or shorten injection interval | | Trough T >700 ng/dL | Reduce dose | | Hematocrit 52 to 54% | Recheck in 4 weeks, encourage hydration, consider dose reduction | | Hematocrit >54% | Hold dose, recheck CBC in 4 to 6 weeks | | PSA rise >1.4 ng/mL from baseline | Urology referral | | New gynecomastia or fluid retention | Check E2; consider aromatase inhibitor if E2 >50 pg/mL |

Every 6 to 12 Months: Long-Term Maintenance Monitoring

Once the patient is on a stable dose with trough testosterone in range and hematocrit below 52%, the monitoring cadence shifts to every 6 to 12 months.

Stable-Phase Lab Panel

• Serum total testosterone (trough)
• CBC with hematocrit
• PSA (annually, or every 6 months if PSA was elevated or velocity was concerning)
• Lipid panel (every 12 months, testosterone modestly suppresses HDL cholesterol)
• CMP (every 12 months)
• Estradiol (every 6 to 12 months or if symptomatic)

Lipid Monitoring: What the Data Show

Exogenous testosterone reduces HDL cholesterol by an average of 5 to 10% at therapeutic doses, though the clinical significance of this reduction in the absence of LDL elevation remains debated. A meta-analysis of 51 randomized trials (N=5,948) found that testosterone therapy reduced HDL by 3.7 mg/dL on average. Corona G et al., European Journal of Endocrinology, 2016. Patients with pre-existing dyslipidemia or cardiovascular disease should have lipids checked at 6 months rather than 12.

Bone Density Monitoring

Men with osteoporosis or low bone mass at baseline should have a DXA scan repeated at 1 to 2 years on therapy. The T-Trials bone sub-trial (N=211) showed that testosterone therapy increased volumetric BMD at the spine by 7.5% and at the hip by 4.1% compared to placebo over 12 months (P<0.001 for both sites). Snyder PJ et al., NEJM 2016, bone sub-trial.

Cardiovascular Monitoring: An Evolving Area

The cardiovascular safety of testosterone replacement therapy has been studied in multiple randomized trials and observational datasets, with conflicting results until recently.

TRAVERSE Trial Findings

The TRAVERSE trial (N=5,246 middle-aged and older men with hypogonadism and pre-existing or high cardiovascular risk) showed that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean 33-month follow-up. However, the testosterone arm had a higher rate of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury. Lincoff AM et al., NEJM 2023. Clinicians managing TRT in men with known cardiovascular disease should document cardiac symptoms at every visit.

Blood Pressure

Testosterone may raise blood pressure modestly through sodium retention (mediated partly by estradiol). Blood pressure should be checked at every in-person visit. Men with stage 2 hypertension (systolic above 160 mmHg) at baseline should have the cardiovascular risk-benefit discussion before starting therapy.

Prostate Monitoring: The Nuanced Picture

The saturation model, proposed by Morgentaler and Traish, holds that androgen receptors in prostate tissue become saturated at relatively low testosterone concentrations (approximately 250 ng/dL). Above that level, additional testosterone does not linearly increase prostate growth. Morgentaler A, Traish AM. European Urology, 2009. This model helps explain why restoring testosterone from castrate to normal physiologic levels does not produce the same prostate growth seen with pharmacologic androgen excess.

Regardless of the saturation model, PSA surveillance remains mandatory. The Endocrine Society 2018 guideline states: "We suggest measuring PSA levels at 3 to 6 months after initiating testosterone therapy." Bhasin S et al., J Clin Endocrinol Metab, 2018.

Special Populations: Adjusted Monitoring Needs

Men Over 65

The T-Trials enrolled men 65 years or older (mean age 72) and found that this cohort showed more pronounced hematocrit elevations than younger men. Older men should have hematocrit checked at 6 weeks and again at 3 months, rather than waiting the full 3-month cycle. Snyder PJ et al., NEJM 2016.

Men with Obesity (BMI >30)

Higher body fat means more aromatase activity, so estradiol levels tend to run higher. These patients may need E2 checked more frequently (every 3 months initially) and are more likely to require dose adjustment. SHBG is also lower in obesity, meaning free testosterone is proportionally higher than total testosterone suggests.

Men with Polycythemia Risk

Prior history of polycythemia vera, sleep apnea, or smoking all raise baseline erythropoiesis. These men should have hematocrit checked monthly for the first 3 months, then every 3 months thereafter, rather than the standard every-6-month schedule.

Fertility Considerations and LH/FSH Monitoring

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback. LH and FSH drop to near-zero within weeks of starting therapy, suppressing intratesticular testosterone and spermatogenesis. Men who want to preserve fertility should not use testosterone cypionate without concurrent HCG or clomiphene citrate to maintain intratesticular testosterone. Ramasamy R et al., J Urol, 2014.

For men on concurrent HCG, LH/FSH monitoring is not informative (HCG bypasses the axis). Semen analysis every 6 months is the more meaningful fertility endpoint for these patients.

Injection Site and Physical Exam at Each Visit

Lab data alone does not complete the monitoring picture. Every in-person or telehealth visit should include:

• Injection site assessment for nodules, abscess, or lipoatrophy (particularly relevant for subcutaneous dosing)
• Testicular volume, progressive atrophy signals HPG suppression
• Breast tissue exam, gynecomastia from E2 elevation can develop within the first 3 months
• Blood pressure measurement
• Symptom scoring using the AMS or IIEF-5 questionnaire to document treatment response objectively

Summary Monitoring Table

| Timepoint | Tests Required | |---|---| | Baseline (pre-treatment) | Total T (x2 morning draws), LH, FSH, SHBG, CBC, CMP, lipids, PSA, E2, prolactin, DXA if indicated | | 6 to 8 weeks (trough draw) | Total T, hematocrit, E2, symptom score | | 3 months | Total T, CBC, PSA, E2, LFTs if indicated | | Every 6 months (stable phase) | Total T, CBC, PSA (if elevated history), E2 | | Every 12 months (stable phase) | All 6-month labs plus lipid panel, CMP, DXA if BMD was low |